Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review
Authors
Keywords
Rosiglitazone, Pioglitazone, Fatty Acid Oxidation, Phytanic Acid, Bezafibrate
Journal
Nutrition Journal
Volume 13, Issue 1, Pages -
Publisher
Springer Nature
Online
2014-02-14
DOI
10.1186/1475-2891-13-17
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dietary supplementation with long-chain monounsaturated fatty acids attenuates obesity-related metabolic dysfunction and increases expression of PPAR gamma in adipose tissue in type 2 diabetic KK-Ay mice
- (2013) Zhi-Hong Yang et al. Nutrition & Metabolism
- A new, highly selective murine peroxisome proliferator-activated receptor δ agonist increases responsiveness to thermogenic stimuli and glucose uptake in skeletal muscle in obese mice
- (2011) R. A. Ngala et al. DIABETES OBESITY & METABOLISM
- The safety of thiazolidinediones
- (2011) Keith G Tolman Expert Opinion On Drug Safety
- Comparative Gene Expression Profiles Induced by PPARγ and PPARα/γ Agonists in Human Hepatocytes
- (2011) Alexandra Rogue et al. PLoS One
- Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
- (2010) T. M. E. Davis et al. DIABETOLOGIA
- Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes
- (2010) Fredrick L. Dunn et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver
- (2010) Alexandra Rogue et al. PPAR Research
- Coactivators in PPAR-Regulated Gene Expression
- (2010) Navin Viswakarma et al. PPAR Research
- Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
- (2009) Laura A. Marlow et al. CANCER RESEARCH
- Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes: The FIELD Helsinki substudy
- (2009) C. Forsblom et al. DIABETES CARE
- Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes
- (2009) John Dormandy et al. DRUG SAFETY
- Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study
- (2009) Robert R Henry et al. LANCET
- Peroxisome Proliferator-Activated Receptor -Mediated Up-regulation of Syndecan-1 by n-3 Fatty Acids Promotes Apoptosis of Human Breast Cancer Cells
- (2008) H. Sun et al. CANCER RESEARCH
- Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats
- (2008) B.-C. Yu et al. CARDIOVASCULAR RESEARCH
- Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event
- (2008) Gerald G. Long et al. TOXICOLOGIC PATHOLOGY
- Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies
- (2008) Mark A. Deeg et al. PPAR Research
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now